Treats human immunodeficiency virus (HIV-1) infection. ANDA 91560, held by Hetero Labs Ltd Iii. Abacavir Sulfate.
As of Nov 16, 2026, ANDA 91560 (Abacavir Sulfate), held by Hetero Labs Ltd Iii, was first approved by FDA on Sep 13, 2013, with 0 approved supplements and 0 published complete response letters.
Abacavir tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (HIV-1) infection. Abacavir, a nucleoside analogue human immunodeficiency virus (HIV-1) reverse transcriptase inhibitor, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 13, 2013 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Abacavir SulfateEQ 300MG BASE · tablet;oral | Abacavir Sulfate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters